Federal Register: December 22, 2006 (Volume 71, Number 246)
DOCID: FR Doc E6-21905
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
NOTICE: NOTICES
ACTION: Patent licenses; non-exclusive, exclusive, or partially exclusive:
DOCUMENT ACTION: Notice.
SUBJECT CATEGORY:
Prospective Grant of Exclusive License: Method of Treating or Preventing Cancer Using Radiosensitizing Agents
DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 20, 2007 will be considered.
DOCUMENT SUMMARY:
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the invention embodied in U.S. Provisional Patent Application No. 60/718,172, filed September 16, 2005, entitled ``Method of Treating or Preventing Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents'' [E 3192005/0US01; E3192005/0PCT02], to Vion Pharmaceuticals, Inc., having a place of business in New Haven, Connecticut. The patent rights in these inventions have been assigned to the United States of America.
The prospective exclusive license territory may be worldwide, and the field of use may be limited to the use of the Triapine as a radiosensitizer as claimed in the licensed patent rights for the treatment of cancer and other tumors.
SUMMARY:
Vion Pharmaceuticals, Inc.,
SUPPLEMENTAL INFORMATION
This technology relates to using 2-
carboxyaldehyde pyridine thiosemicarbazone compounds or prodrugs thereof, specifically 3amino2carboxyaldehyde pyridine
thiosemicarbazone (Triapine) or 4methyl3amino2carbozyaldehyde
pyridine thiosemicarbazone, as radiosensitizing agents prior to administering ionizing radiation.
[[Page 77039]]
The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR Part 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
Dated: December 13, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.
[FR Doc. E621905 Filed 122106; 8:45 am]
BILLING CODE 414001P